However, doctors can use brain scans or spinal tubes to detect Alzheimer's in patients, apparently there is no way to check the disease in healthy individuals. Still, alzheimers can still digest the brain for many decades – before anyone can wrongly validate anything. The inability to find Alzheimer's early detection is a major cause, pharmaceutical companies are not able to develop the drug to combat the disease, which is the most common form of dementia.
Researchers at Washington University at St. Louis and the German Center for German Diagnostic Diseases of Tubingan have developed a simple blood test that shows evidence of Alzheimer's brain damage, about seven years before any kind of cognitive changes occur. In theory, this test can be used to find patients who will advance to develop the disease, so that they can enter the drug trail in the near future and can be saved from developing dementia in the long run. His work publication (Pavel) was published Monday (January 21) in Nature Medicine.
This study included a group of people in the Dominion-Enhanced Alzheimer's network. This network is made up of one of the three genetic mutations that guarantee that they guarantee the beginning of Alzheimer's and some of their family members, in which there is no change from them. In total, only one% of Alzheimer's cases occur by one of these three mutations.
Researchers took samples of blood from 243 people, who were one of the mutations, and 162 who did not do six or nine years in their 40s or 50s, every three years or three to six years. They saw the protein level called "neurophilicate light chain", which provides structural support for neurons. Although scientists do not know a lot about this protein, high levels of blood usually indicate brain damage. They are shown in the blood of college football players after the pavilion season, and in the blood of Alzheimer's and other forms of dementia (pavilion).
Each person in the study had the amount of neurophilicate light chain in their blood, and was to develop more with that time. However, those who had inherited hereditary Alzheimer's gene began to accumulate proteins in their blood at a faster rate than people without jeans.
The predominantly hereditary alzheimer's prediction is predicted, so scientists have a good idea when patients begin to show symptoms. Research teams have found that on the basis of prediction, people are believed to have high levels of neurofilament light chains in the blood six years and nine months before showing dementia symptoms. Without change, their family members had lower levels of the neurophilite light chain at that time. (Ultimately, scientists predict Alzheimer's may be able to identify specific amounts of neurophilamous light chains in the blood, but this is not a big study to establish that level.)
After every two years of starting the study in this study, brain scans and cognitive tests were also carried out on 39 people, primarily in studies involving Alzheimer's inherited studies. Sufficiently, high levels of neurophilamine light chains in the blood, bad memory and blood associated with executive function, and degradation in the brain part associated with memory.
The blood test is still in the US Has been approved by the Food and Drug Administration. Washington University's radiologist and psychologist Brian Gordon said in a statement that he imagines that doctors can give it to their patients or it takes only a few years before it can be used in a clinical trial.